EuroBiotech: More Articles of Note


> Avacta committed to moving its tumor microenvironment activated drug conjugate into the clinic ahead of schedule. Testing in humans is due to start next year. Statement   

> Themis Bioscience secured up to $21 million (€19 million) in non-dilutive funding to support a phase 3 trial of its Chikungunya vaccine. Filings to start the trial are planned for later this year. Release  

> Merck KGaA published interim data from a phase 2 trial of tepotinib in non-small cell lung cancer. The trial linked the MET kinase inhibitor to a response rate of around 50%. Statement 


De-risking the Development of Biotherapeutics Using Early Stage In Vitro Expression and Genetic Characterisation Tools

There is a high attrition rate during the development of biotherapeutics impacting the high cost of development. Early identification of the preferred expression host for manufacturing, along with lead candidate screening and material supply can help to reduce both attrition rates and cost.

> Sotio’s autologous immunotherapy achieved a 15.5 month overall survival in stage 4 non-small cell lung cancer, as compared to 11.8 months in the control arm. Release 

> BerGenBio presented updated data from a trial of bemcentinib and low-intensity chemotherapy in elderly acute myeloid leukemia patients. About half of the subjects responded to the regimen. Statement   

> Corbin Therapeutics licensed neuroinflammation assets from the University of Dundee Drug Discovery Unit. Release  

Suggested Articles

Antivirals from Roche, Bristol Myers Squibb, Viiv and Gilead, or modified versions of them, could prove effective against COVID-19, researchers said.

After posting positive data that showed it could help slow down the degenerative ALS disease, Amylyx has been given a $30 million boost.

Sumitomo is looking to the merged pipeline to help offset the anticipated impact of the arrival of generic competitors to bipolar drug Latuda.